8 news items
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
ASND
14 May 24
face an urgent need for new treatments." About Ascendis Pharma A/S Ascendis Pharma is applying its innovative
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
ASND
13 May 24
. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
ASND
9 May 24
. and in China through VISEN Pharmaceuticals. About Ascendis Pharma A/SAscendis Pharma is applying its innovative
Ascendis Pharma Reports First Quarter 2024 Financial Results
ASND
2 May 24
its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
ASND
25 Apr 24
is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference
biao8rjzhzibltv l6vxfohlw
ASND
24 Apr 24
innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives
jwpk5u1044vui4nqxx7fuwi0z1dvu0efwtl7v6
ASND
4 Mar 24
for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform
9n2jd dru2b9dsxw6nd9mwvnv7
AAPL
AMZN
ASND
3 Mar 24
is bullish on, Ascendis Pharma stands out for its innovative TransCon drug development platform, which promises to improve patient outcomes
- Prev
- 1
- Next